1. Home
  2. ELLO vs TENX Comparison

ELLO vs TENX Comparison

Compare ELLO & TENX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

ELLO

Ellomay Capital Ltd (Israel)

N/A

Current Price

$19.01

Market Cap

337.7M

Sector

Utilities

ML Signal

N/A

Logo Tenax Therapeutics Inc.

TENX

Tenax Therapeutics Inc.

HOLD

Current Price

$13.64

Market Cap

317.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ELLO
TENX
Founded
1987
1967
Country
Israel
United States
Employees
N/A
N/A
Industry
Electric Utilities: Central
Biotechnology: Pharmaceutical Preparations
Sector
Utilities
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
337.7M
317.8M
IPO Year
1998
2001

Fundamental Metrics

Financial Performance
Metric
ELLO
TENX
Price
$19.01
$13.64
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$29.67
AVG Volume (30 Days)
7.5K
892.4K
Earning Date
03-31-2026
05-15-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$15.40
$5.67
52 Week High
$30.34
$18.38

Technical Indicators

Market Signals
Indicator
ELLO
TENX
Relative Strength Index (RSI) 28.96 67.28
Support Level $17.14 $13.16
Resistance Level $19.66 $14.15
Average True Range (ATR) 0.96 0.72
MACD -0.23 0.30
Stochastic Oscillator 0.41 99.40

Price Performance

Historical Comparison
ELLO
TENX

About ELLO Ellomay Capital Ltd (Israel)

Ellomay Capital Ltd is a renewable energy company. It develops and operates renewable energy projects in Europe, the USA, and Israel, employing diverse technologies such as solar power, natural gas, pumped hydro, and waste-to-energy solutions.

About TENX Tenax Therapeutics Inc.

Tenax Therapeutics Inc is a phase three, development-stage pharmaceutical company focused on identifying and developing therapeutics that address cardiovascular and pulmonary diseases with high unmet medical need, with an initial therapeutic focus on pulmonary hypertension. Its drug development pipeline comprises: Levosimendan, a novel, first-in-class K-ATP activator and calcium sensitizer developed for intravenous use in hospitalized patients with acutely decompensated heart failure; and Imatinib, as a potential therapy for pulmonary arterial hypertension. The company is currently conducting clinical trials only for levosimendan as its prioritized product candidate to evaluate its potential to help patients with pulmonary hypertension.

Share on Social Networks: